TeleECHO Sessions
Project ECHO® is a lifelong learning and guided practice model that revolutionizes online CME courses and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO® model™ is its expansive knowledge-sharing network, led by expert teams who use multipoint videoconferencing to conduct online CME courses and virtual clinics with community providers. In this way, ECHO® allows CME providers to foster problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities. The Project ECHO® format fosters dialogue in a way most online CME courses don’t, and asking any questions you may have on the topic or a patient case in a Health Insurance Portability and Accountability Act (HIPAA) compliant manner is encouraged.
Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas: Summarizing Current Efficacy and Safety Data (Podcasts)
Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Thursday, February 19, 2026
12:00 p.m. – 1:00 p.m. ET
Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Friday, February 27, 2026
12:00 p.m. – 1:00 p.m. ET
Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Wednesday, March 4, 2026
3:00 p.m. – 4:00 p.m. ET
Please note this TeleECHO program is 3:00 p.m. Eastern, 2:00 p.m. Central, 1:00 p.m. Mountain and 12:00 p.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Monday, March 9, 2026
12:00 p.m. – 1:00 p.m. ET
Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Thursday, March 19, 2026
1:00 p.m. – 2:00 p.m. ET
Please note this TeleECHO program is 1:00 p.m. Eastern, 12:00 p.m. Central, 11:00 a.m. Mountain and 10:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Monday, March 23, 2026
12:00 p.m. – 1:00 p.m. ET
Please note this TeleECHO program is 12:00 p.m. Eastern, 11:00 a.m. Central, 10:00 a.m. Mountain and 9:00 a.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Tuesday, March 31, 2026
7:00 p.m. – 6:00 p.m. ET
Please note this TeleECHO program is 7:00 p.m. Eastern, 6:00 p.m. Central, 5:00 p.m. Mountain and 4:00 p.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Wednesday, April 8, 2026
7:00 p.m. – 6:00 p.m. ET
Please note this TeleECHO program is 7:00 p.m. Eastern, 6:00 p.m. Central, 5:00 p.m. Mountain and 4:00 p.m. Pacific.
Strategies for Applying HER2-Targeted Antibody-Drug Conjugates Across HER2-Expressing Solid Tumors
Monday, April 13, 2026
3:00 p.m. – 4:00 p.m. ET
Please note this TeleECHO program is 3:00 p.m. Eastern, 2:00 p.m. Central, 1:00 p.m. Mountain and 12:00 p.m. Pacific.